Skip to main content
Premium Trial:

Request an Annual Quote

Wall-to-Wall Bioinformatics

Next Generation Technologist ponders whether the market can really support the slew of bioinformatics companies popping up to analyze data from next-gen sequencers.

Citing a list compiled by Geoffrey Routh that includes 90 informatics firms — from Abiomics to Woodward Informatics — Dale Yuzuki notes that "new companies are being formed, large software and hardware firms are expanding into the life sciences, and others are offering in addition to software options the implementation of a cloud-based service."

But "can the market absorb all these new offerings?" he asks. As has been the case in bioinformatics for more than a decade, most genomic research groups still rely on open source software to do their analysis — in large part because most research grants do not include funds for purchasing software. "It's hard to compete with free," Yuzuki says.

Nevertheless, he notes that the field is still in its infancy and there is no recognized "best way" to perform genomic analysis, leaving the sector wide open for the proliferation of startups with novel methods. "We are in a phase of the market that will tolerate a lot of creative approaches before the inevitable pruning begins," he says.

"Is there room for 90 companies to produce software or provide software as a service for genomics? Eventually, definitely not," he says. In the meantime, "a hundred flowers bloom."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.